Supplementary Figures 15 - 17, Table 8 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

Riester, Markus; Werner, Lillian; Bellmunt, Joaquim; Selvarajah, Shamini; Guancial, Elizabeth A.; Weir, Barbara A.; Stack, Edward C.; Park, Rachel S.; O'Brien, Robert; Schutz, Fabio A.B.; Choueiri, Toni K.; Signoretti, Sabina; Lloreta, Josep; Marchionni, Luigi; Gallardo, Enrique; Rojo, Federico; Garcia, Denise I.; Chekaluk, Yvonne; Kwiatkowski, David J.; Bochner, Bernard H.; Hahn, William C.; Ligon, Azra H.; Barletta, Justine A.; Loda, Massimo; Berman, David M.; Kantoff, Philip W.; Michor, Franziska; Rosenberg, Jonathan E.

doi:10.1158/1078-0432.22452383.v1

Supplementary Figures 15 - 17, Table 8 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

https://doi.org/10.1158/1078-0432.22452383

journal contribution

posted on 2023-03-31, 17:52 authored by Markus Riester, Lillian Werner, Joaquim Bellmunt, Shamini Selvarajah, Elizabeth A. Guancial, Barbara A. Weir, Edward C. Stack, Rachel S. Park, Robert O'Brien, Fabio A.B. Schutz, Toni K. Choueiri, Sabina Signoretti, Josep Lloreta, Luigi Marchionni, Enrique Gallardo, Federico Rojo, Denise I. Garcia, Yvonne Chekaluk, David J. Kwiatkowski, Bernard H. Bochner, William C. Hahn, Azra H. Ligon, Justine A. Barletta, Massimo Loda, David M. Berman, Philip W. Kantoff, Franziska Michor, Jonathan E. Rosenberg

<p>PDF file - 452KB, Independent validation; Validation of 1q23.3 survival association in independent cohorts; Figure S15: Expression of genes on 1q23.3 in an independent cohort 3; S16: Expression of genes on 1q23.3 as in Supplemental Figure S15, but in the Spanish (a-b) and DFCI (c-d) cohorts. Panels (a) and (c) are for samples with 1q23.3 gain or amplification (log2 copy number ratio > 0.15), (b) and (d) for patients without amplification; S17: Panel (a): No association of overall survival after surgery and 1q23.3 amplification in an inde- pendent cohort from DFCI. (b) No significant association of 1q23.3 amplification and OS after recurrence, possibly due to small patient numbers; Table S8: Overall survival (OS) Hazard Ratios (HRs) of genes in the three peaks, available on the Affymetrix HGU133 Plus 2.0 genechip and displaying patterns of gene expression different from background noise as identified by the Sleipnir library 1. The LMX1A gene was flat, i.e., showed minimum expression intensity in all patients. Table S9: Overall survival (OS) Hazard Ratios (HRs) of genes in 1q21.2 as in Supplementary Table S8.</p>

History

Related Materials

1.
DOI - Is supplement to Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

ARTICLE ABSTRACT

Purpose: Metastatic urothelial carcinoma of the bladder is associated with multiple somatic copy-number alterations (SCNAs). We evaluated SCNAs to identify predictors of poor survival in patients with metastatic urothelial carcinoma treated with platinum-based chemotherapy.Experimental Design: We obtained overall survival (OS) and array DNA copy-number data from patients with metastatic urothelial carcinoma in two cohorts. Associations between recurrent SCNAs and OS were determined by a Cox proportional hazard model adjusting for performance status and visceral disease. mRNA expression was evaluated for potential candidate genes by NanoString nCounter to identify transcripts from the region that are associated with copy-number gain. In addition, expression data from an independent cohort were used to identify candidate genes.Results: Multiple areas of recurrent significant gains and losses were identified. Gain of 1q23.3 was independently associated with a shortened OS in both cohorts [adjusted HR, 2.96; 95% confidence interval (CI), 1.35–6.48; P = 0.01 and adjusted HR, 5.03; 95% CI, 1.43–17.73; P < 0.001]. The F11R, PFDN2, PPOX, USP21, and DEDD genes, all located on 1q23.3, were closely associated with poor outcome.Conclusions: 1q23.3 copy-number gain displayed association with poor survival in two cohorts of metastatic urothelial carcinoma. The identification of the target of this copy-number gain is ongoing, and exploration of this finding in other disease states may be useful for the early identification of patients with poor-risk urothelial carcinoma. Prospective validation of the survival association is necessary to demonstrate clinical relevance. Clin Cancer Res; 20(7); 1873–83. ©2014 AACR.

Supplementary Figures 15 - 17, Table 8 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

History

Related Materials

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports